Immune Control and Vaccination against the Epstein–Barr Virus in Humanized Mice
Abstract
1. Introduction on the Epstein Barr Virus
2. Modelling Tumorigenesis and Immune Pathology by EBV in Humanized Mice
3. Characteristics of Cell-Mediated Immune Control against EBV in Humanized Mice
4. Adoptive EBV-Specific T Cell Transfer in Humanized Mice
5. Vaccination against EBV in Humanized Mice
6. Conclusions and Outlook
Funding
Conflicts of Interest
References
- Münz, C. Latency and lytic replication in the oncogenesis of the Epstein Barr virus. Nat. Rev. Micobiol. 2019, 17, 691–700. [Google Scholar] [CrossRef]
- Thorley-Lawson, D.A. Epstein-Barr virus: Exploiting the immune system. Nat. Rev. Immunol. 2001, 1, 75–82. [Google Scholar] [CrossRef]
- Frost, T.C.; Gewurz, B.E. Epigenetic crossroads of the Epstein-Barr virus B-cell relationship. Curr. Opin. Virol. 2018, 32, 15–23. [Google Scholar] [CrossRef] [PubMed]
- Kalchschmidt, J.S.; Bashford-Rogers, R.; Paschos, K.; Gillman, A.C.; Styles, C.T.; Kellam, P.; Allday, M.J. Epstein-Barr virus nuclear protein EBNA3C directly induces expression of AID and somatic mutations in B cells. J. Exp. Med. 2016, 213, 921–928. [Google Scholar] [CrossRef] [PubMed]
- Ramiro, A.R.; Jankovic, M.; Eisenreich, T.; Difilippantonio, S.; Chen-Kiang, S.; Muramatsu, M.; Honjo, T.; Nussenzweig, A.; Nussenzweig, M.C. AID is required for c-myc/IgH chromosome translocations in vivo. Cell 2004, 118, 431–438. [Google Scholar] [CrossRef] [PubMed]
- Shannon-Lowe, C.; Rickinson, A. The global landscape of EBV-associated tumors. Front. Oncol. 2019, 9, 713. [Google Scholar] [CrossRef] [PubMed]
- Cesarman, E. Gammaherpesviruses and lymphoproliferative disorders. Annu. Rev. Pathol. 2014, 9, 349–372. [Google Scholar] [CrossRef]
- Cohen, J.I.; Fauci, A.S.; Varmus, H.; Nabel, G.J. Epstein-Barr virus: An important vaccine target for cancer prevention. Sci. Transl. Med. 2011, 3, 107fs107. [Google Scholar] [CrossRef]
- Parkin, D.M. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 2006, 118, 3030–3044. [Google Scholar] [CrossRef]
- Bouvard, V.; Baan, R.; Straif, K.; Grosse, Y.; Secretan, B.; El Ghissassi, F.; Benbrahim-Tallaa, L.; Guha, N.; Freeman, C.; Galichet, L.; et al. A review of human carcinogens--part B: Biological agents. Lancet Oncol. 2009, 10, 321–322. [Google Scholar] [CrossRef]
- Taylor, G.S.; Long, H.M.; Brooks, J.M.; Rickinson, A.B.; Hislop, A.D. The immunology of Epstein-Barr virus-induced disease. Annu. Rev. Immunol. 2015, 33, 787–821. [Google Scholar] [CrossRef]
- Dunmire, S.K.; Verghese, P.S.; Balfour, H.H., Jr. Primary Epstein-Barr virus infection. J. Clin. Virol. 2018, 102, 84–92. [Google Scholar] [CrossRef] [PubMed]
- Al-Samkari, H.; Berliner, N. Hemophagocytic lymphohistiocytosis. Annu. Rev. Pathol. 2018, 13, 27–49. [Google Scholar] [CrossRef] [PubMed]
- Ascherio, A.; Munger, K.L.; Lünemann, J.D. The initiation and prevention of multiple sclerosis. Nat. Rev. Neurol. 2012, 8, 602–612. [Google Scholar] [CrossRef] [PubMed]
- Latour, S.; Fischer, A. Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases. Immunol. Rev. 2019, 291, 174–189. [Google Scholar] [CrossRef] [PubMed]
- Damania, B.; Münz, C. Immunodeficiencies that predispose to pathologies by human oncogenic gamma-herpesviruses. FEMS Microbiol. Rev. 2019, 43, 181–192. [Google Scholar] [CrossRef] [PubMed]
- Balfour, H.H., Jr.; Odumade, O.A.; Schmeling, D.O.; Mullan, B.D.; Ed, J.A.; Knight, J.A.; Vezina, H.E.; Thomas, W.; Hogquist, K.A. Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J. Infect. Dis. 2013, 207, 80–88. [Google Scholar] [CrossRef]
- Dunmire, S.K.; Grimm, J.M.; Schmeling, D.O.; Balfour, H.H., Jr.; Hogquist, K.A. The incubation period of primary Epstein-Barr virus infection: Viral dynamics and immunologic events. PLoS Pathog. 2015, 11, e1005286. [Google Scholar] [CrossRef]
- Moutschen, M.; Leonard, P.; Sokal, E.M.; Smets, F.; Haumont, M.; Mazzu, P.; Bollen, A.; Denamur, F.; Peeters, P.; Dubin, G.; et al. Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine 2007, 25, 4697–4705. [Google Scholar] [CrossRef]
- Sokal, E.M.; Hoppenbrouwers, K.; Vandermeulen, C.; Moutschen, M.; Leonard, P.; Moreels, A.; Haumont, M.; Bollen, A.; Smets, F.; Denis, M. Recombinant gp350 vaccine for infectious mononucleosis: A phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J. Infect. Dis. 2007, 196, 1749–1753. [Google Scholar] [CrossRef]
- Ehlers, B.; Spiess, K.; Leendertz, F.; Peeters, M.; Boesch, C.; Gatherer, D.; McGeoch, D.J. Lymphocryptovirus phylogeny and the origins of Epstein-Barr virus. J. Gen. Virol. 2010, 91, 630–642. [Google Scholar] [CrossRef] [PubMed]
- Traggiai, E.; Chicha, L.; Mazzucchelli, L.; Bronz, L.; Piffaretti, J.C.; Lanzavecchia, A.; Manz, M.G. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004, 304, 104–107. [Google Scholar] [CrossRef] [PubMed]
- Yajima, M.; Imadome, K.; Nakagawa, A.; Watanabe, S.; Terashima, K.; Nakamura, H.; Ito, M.; Shimizu, N.; Honda, M.; Yamamoto, N.; et al. A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J. Infect. Dis. 2008, 198, 673–682. [Google Scholar] [CrossRef] [PubMed]
- Ma, S.D.; Hegde, S.; Young, K.H.; Sullivan, R.; Rajesh, D.; Zhou, Y.; Jankowska-Gan, E.; Burlingham, W.J.; Sun, X.; Gulley, M.L.; et al. A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J. Virol. 2011, 85, 165–177. [Google Scholar] [CrossRef]
- Shultz, L.D.; Saito, Y.; Najima, Y.; Tanaka, S.; Ochi, T.; Tomizawa, M.; Doi, T.; Sone, A.; Suzuki, N.; Fujiwara, H.; et al. Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/scid/IL2R gammanull humanized mice. Proc. Natl. Acad. Sci. USA 2010, 107, 13022–13027. [Google Scholar] [CrossRef]
- Strowig, T.; Gurer, C.; Ploss, A.; Liu, Y.F.; Arrey, F.; Sashihara, J.; Koo, G.; Rice, C.M.; Young, J.W.; Chadburn, A.; et al. Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J. Exp. Med. 2009, 206, 1423–1434. [Google Scholar] [CrossRef]
- Melkus, M.W.; Estes, J.D.; Padgett-Thomas, A.; Gatlin, J.; Denton, P.W.; Othieno, F.A.; Wege, A.K.; Haase, A.T.; Garcia, J.V. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat. Med. 2006, 12, 1316–1322. [Google Scholar] [CrossRef]
- Murer, A.; McHugh, D.; Caduff, N.; Kalchschmidt, J.S.; Barros, M.H.; Zbinden, A.; Capaul, R.; Niedobitek, G.; Allday, M.J.; Chijioke, O.; et al. EBV persistence without its EBNA3A and 3C oncogenes in vivo. PLoS Pathog. 2018, 14, e1007039. [Google Scholar] [CrossRef]
- White, R.E.; Ramer, P.C.; Naresh, K.N.; Meixlsperger, S.; Pinaud, L.; Rooney, C.; Savoldo, B.; Coutinho, R.; Bodor, C.; Gribben, J.; et al. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J. Clin. Investig. 2012, 122, 1487–1502. [Google Scholar] [CrossRef]
- Gottschalk, S.; Ng, C.Y.; Perez, M.; Smith, C.A.; Sample, C.; Brenner, M.K.; Heslop, H.E.; Rooney, C.M. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 2001, 97, 835–843. [Google Scholar] [CrossRef]
- Cesarman, E. Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients. Cancer Lett. 2011, 305, 163–174. [Google Scholar] [CrossRef] [PubMed]
- Klein, U.; Gloghini, A.; Gaidano, G.; Chadburn, A.; Cesarman, E.; Dalla-Favera, R.; Carbone, A. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 2003, 101, 4115–4121. [Google Scholar] [CrossRef] [PubMed]
- McHugh, D.; Caduff, N.; Barros, M.H.M.; Rämer, P.; Raykova, A.; Murer, A.; Landtwing, V.; Quast, I.; Styles, C.T.; Spohn, M.; et al. Persistent KSHV infection increases EBV-associated tumor formation in vivo via enhanced EBV lytic gene expression. Cell Host Microbe 2017, 22, 61–73. [Google Scholar] [CrossRef] [PubMed]
- Ma, S.D.; Yu, X.; Mertz, J.E.; Gumperz, J.E.; Reinheim, E.; Zhou, Y.; Tang, W.; Burlingham, W.J.; Gulley, M.L.; Kenney, S.C. An Epstein-Barr virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model. J. Virol. 2012, 86, 7976–7987. [Google Scholar] [CrossRef] [PubMed]
- Bristol, J.A.; Djavadian, R.; Albright, E.R.; Coleman, C.B.; Ohashi, M.; Hayes, M.; Romero-Masters, J.C.; Barlow, E.A.; Farrell, P.J.; Rochford, R.; et al. A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infection. PLoS Pathog. 2018, 14, e1007179. [Google Scholar] [CrossRef]
- McHugh, D.; Caduff, N.; Murer, A.; Engelmann, C.; Deng, Y.; Zdimerova, H.; Zens, K.; Chijioke, O.; Münz, C. Infection and immune control of human oncogenic gamma-herpesviruses in humanized mice. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2019, 374, 20180296. [Google Scholar] [CrossRef]
- Heuts, F.; Rottenberg, M.E.; Salamon, D.; Rasul, E.; Adori, M.; Klein, G.; Klein, E.; Nagy, N. T cells modulate Epstein-Barr virus latency phenotypes during infection of humanized mice. J. Virol. 2014, 88, 3235–3245. [Google Scholar] [CrossRef]
- Chatterjee, B.; Deng, Y.; Holler, A.; Nunez, N.; Azzi, T.; Vanoaica, L.D.; Müller, A.; Zdimerova, H.; Antsiferova, O.; Zbinden, A.; et al. CD8+ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein-Barr virus infection in vivo. PLoS Pathog. 2019, 15, e1007748. [Google Scholar] [CrossRef]
- Callan, M.F.; Steven, N.; Krausa, P.; Wilson, J.D.; Moss, P.A.; Gillespie, G.M.; Bell, J.I.; Rickinson, A.B.; McMichael, A.J. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat. Med. 1996, 2, 906–911. [Google Scholar] [CrossRef]
- Callan, M.F.; Tan, L.; Annels, N.; Ogg, G.S.; Wilson, J.D.; O’Callaghan, C.A.; Steven, N.; McMichael, A.J.; Rickinson, A.B. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med. 1998, 187, 1395–1402. [Google Scholar] [CrossRef]
- Antsiferova, O.; Müller, A.; Rämer, P.; Chijioke, O.; Chatterjee, B.; Raykova, A.; Planas, R.; Sospedra, M.; Shumilov, A.; Tsai, M.H.; et al. Adoptive transfer of EBV specific CD8+ T cell clones can transiently control EBV infection in humanized mice. PLoS Pathog. 2014, 10, e1004333. [Google Scholar] [CrossRef] [PubMed]
- Yoshihara, S.; Li, Y.; Xia, J.; Danzl, N.; Sykes, M.; Yang, Y.G. Posttransplant hemophagocytic lymphohistiocytosis driven by myeloid cytokines and vicious cycles of T-cell and macrophage activation in humanized mice. Front. Immunol. 2019, 10, 186. [Google Scholar] [CrossRef] [PubMed]
- Fujiwara, S.; Imadome, K.; Takei, M. Modeling EBV infection and pathogenesis in new-generation humanized mice. Exp. Mol. Med. 2015, 47, e135. [Google Scholar] [CrossRef] [PubMed]
- Zayoud, M.; El Malki, K.; Frauenknecht, K.; Trinschek, B.; Kloos, L.; Karram, K.; Wanke, F.; Georgescu, J.; Hartwig, U.F.; Sommer, C.; et al. Subclinical CNS inflammation as response to a myelin antigen in humanized mice. J. Neuroimmune Pharmacol. 2013, 8, 1037–1047. [Google Scholar] [CrossRef] [PubMed]
- Honeycutt, J.B.; Liao, B.; Nixon, C.C.; Cleary, R.A.; Thayer, W.O.; Birath, S.L.; Swanson, M.D.; Sheridan, P.; Zakharova, O.; Prince, F.; et al. T cells establish and maintain CNS viral infection in HIV-infected humanized mice. J. Clin. Investig. 2018, 128, 2862–2876. [Google Scholar] [CrossRef] [PubMed]
- Grant, M.L.; Bollard, C.M. Cell therapies for hematological malignancies: Don’t forget non-gene-modified T cells! Blood Rev. 2018, 32, 203–224. [Google Scholar] [CrossRef]
- Gujer, C.; Murer, A.; Muller, A.; Vanoaica, D.; Sutter, K.; Jacque, E.; Fournier, N.; Kalchschmidt, J.; Zbinden, A.; Capaul, R.; et al. Plasmacytoid dendritic cells respond to Epstein-Barr virus infection with a distinct type I interferon subtype profile. Blood Adv. 2019, 3, 1129–1144. [Google Scholar] [CrossRef]
- Li, Y.; Masse-Ranson, G.; Garcia, Z.; Bruel, T.; Kok, A.; Strick-Marchand, H.; Jouvion, G.; Serafini, N.; Lim, A.I.; Dusseaux, M.; et al. A human immune system mouse model with robust lymph node development. Nat. Methods 2018, 15, 623–630. [Google Scholar] [CrossRef]
- Yajima, M.; Imadome, K.; Nakagawa, A.; Watanabe, S.; Terashima, K.; Nakamura, H.; Ito, M.; Shimizu, N.; Yamamoto, N.; Fujiwara, S. T cell-mediated control of Epstein-Barr virus infection in humanized mice. J. Infect. Dis. 2009, 200, 1611–1615. [Google Scholar] [CrossRef]
- Chijioke, O.; Muller, A.; Feederle, R.; Barros, M.H.; Krieg, C.; Emmel, V.; Marcenaro, E.; Leung, C.S.; Antsiferova, O.; Landtwing, V.; et al. Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection. Cell Rep. 2013, 5, 1489–1498. [Google Scholar] [CrossRef]
- Landtwing, V.; Raykova, A.; Pezzino, G.; Beziat, V.; Marcenaro, E.; Graf, C.; Moretta, A.; Capaul, R.; Zbinden, A.; Ferlazzo, G.; et al. Cognate HLA absence in trans diminishes human NK cell education. J. Clin. Investig. 2016, 126, 3772–3782. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Murer, A.; Ruhl, J.; Zbinden, A.; Capaul, R.; Hammerschmidt, W.; Chijioke, O.; Münz, C. MicroRNAs of Epstein-Barr virus attenuate T-cell-mediated immune control in vivo. MBio 2019, 10, e01941-18. [Google Scholar] [CrossRef] [PubMed]
- Chijioke, O.; Marcenaro, E.; Moretta, A.; Capaul, R.; Münz, C. The SAP-dependent 2B4 receptor mediates CD8+ T cell dependent immune control of Epstein Barr virus infection in mice with reconstituted human immune system components. J. Infect. Dis. 2015, 212, 803–807. [Google Scholar] [CrossRef] [PubMed]
- Leong, Y.A.; Chen, Y.; Ong, H.S.; Wu, D.; Man, K.; Deleage, C.; Minnich, M.; Meckiff, B.J.; Wei, Y.; Hou, Z.; et al. CXCR5+ follicular cytotoxic T cells control viral infection in B cell follicles. Nat. Immunol. 2016, 17, 1187–1196. [Google Scholar] [CrossRef]
- Ahmed, M.; Lopez-Albaitero, A.; Pankov, D.; Santich, B.H.; Liu, H.; Yan, S.; Xiang, J.; Wang, P.; Hasan, A.N.; Selvakumar, A.; et al. TCR-mimic bispecific antibodies targeting LMP2a show potent activity against EBV malignancies. JCI Insight 2018, 3, e97805. [Google Scholar] [CrossRef]
- Cho, H.I.; Kim, U.H.; Shin, A.R.; Won, J.N.; Lee, H.J.; Sohn, H.J.; Kim, T.G. A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy. Br. J. Cancer 2018, 118, 534–545. [Google Scholar] [CrossRef]
- Bollard, C.M.; Gottschalk, S.; Torrano, V.; Diouf, O.; Ku, S.; Hazrat, Y.; Carrum, G.; Ramos, C.; Fayad, L.; Shpall, E.J.; et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J. Clin. Oncol. 2014, 32, 798–808. [Google Scholar] [CrossRef]
- Azzi, T.; Lunemann, A.; Murer, A.; Ueda, S.; Beziat, V.; Malmberg, K.J.; Staubli, G.; Gysin, C.; Berger, C.; Münz, C.; et al. Role for early-differentiated natural killer cells in infectious mononucleosis. Blood 2014, 124, 2533–2543. [Google Scholar] [CrossRef]
- Hendricks, D.W.; Balfour, H.H., Jr.; Dunmire, S.K.; Schmeling, D.O.; Hogquist, K.A.; Lanier, L.L. Cutting edge: NKG2ChiCD57+ NK cells respond specifically to acute infection with cytomegalovirus and not Epstein-Barr virus. J. Immunol. 2014, 192, 4492–4496. [Google Scholar] [CrossRef]
- Xiang, Z.; Liu, Y.; Zheng, J.; Liu, M.; Lv, A.; Gao, Y.; Hu, H.; Lam, K.T.; Chan, G.C.; Yang, Y.; et al. Targeted activation of human Vgamma9Vdelta2-T cells controls Epstein-Barr virus-induced B cell lymphoproliferative disease. Cancer Cell 2014, 26, 565–576. [Google Scholar] [CrossRef]
- Zumwalde, N.A.; Sharma, A.; Xu, X.; Ma, S.; Schneider, C.L.; Romero-Masters, J.C.; Hudson, A.W.; Gendron-Fitzpatrick, A.; Kenney, S.C.; Gumperz, J.E. Adoptively transferred Vgamma9Vdelta2 T cells show potent antitumor effects in a preclinical B cell lymphomagenesis model. JCI Insight 2017, 2. [Google Scholar] [CrossRef] [PubMed]
- Yuling, H.; Ruijing, X.; Li, L.; Xiang, J.; Rui, Z.; Yujuan, W.; Lijun, Z.; Chunxian, D.; Xinti, T.; Wei, X.; et al. EBV-induced human CD8+ NKT cells suppress tumorigenesis by EBV-associated malignancies. Cancer Res. 2009, 69, 7935–7944. [Google Scholar] [CrossRef] [PubMed]
- Heller, K.N.; Gurer, C.; Münz, C. Virus-specific CD4+ T cells: Ready for direct attack. J. Exp. Med. 2006, 203, 805–808. [Google Scholar] [CrossRef] [PubMed]
- Münz, C.; Bickham, K.L.; Subklewe, M.; Tsang, M.L.; Chahroudi, A.; Kurilla, M.G.; Zhang, D.; O’Donnell, M.; Steinman, R.M. Human CD4+ T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J. Exp. Med. 2000, 191, 1649–1660. [Google Scholar] [CrossRef]
- Paludan, C.; Bickham, K.; Nikiforow, S.; Tsang, M.L.; Goodman, K.; Hanekom, W.A.; Fonteneau, J.F.; Stevanovic, S.; Münz, C. EBNA1 specific CD4+ Th1 cells kill Burkitt’s lymphoma cells. J. Immunol. 2002, 169, 1593–1603. [Google Scholar] [CrossRef]
- Nikiforow, S.; Bottomly, K.; Miller, G.; Münz, C. Cytolytic CD4+-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation. J. Virol. 2003, 77, 12088–12104. [Google Scholar] [CrossRef]
- Meixlsperger, S.; Leung, C.S.; Ramer, P.C.; Pack, M.; Vanoaica, L.D.; Breton, G.; Pascolo, S.; Salazar, A.M.; Dzionek, A.; Schmitz, J.; et al. CD141+ dendritic cells produce prominent amounts of IFN-alpha after dsRNA recognition and can be targeted via DEC-205 in humanized mice. Blood 2013, 121, 5034–5044. [Google Scholar] [CrossRef]
- Adhikary, D.; Behrends, U.; Moosmann, A.; Witter, K.; Bornkamm, G.W.; Mautner, J. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J. Exp. Med. 2006, 203, 995–1006. [Google Scholar] [CrossRef]
- Linnerbauer, S.; Behrends, U.; Adhikary, D.; Witter, K.; Bornkamm, G.W.; Mautner, J. Virus and autoantigen-specific CD4+ T cells are key effectors in a scid mouse model of EBV-associated post-transplant lymphoproliferative disorders. PLoS Pathog. 2014, 10, e1004068. [Google Scholar] [CrossRef]
- Amyes, E.; Hatton, C.; Montamat-Sicotte, D.; Gudgeon, N.; Rickinson, A.B.; McMichael, A.J.; Callan, M.F. Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection. J. Exp. Med. 2003, 198, 903–911. [Google Scholar] [CrossRef]
- Ouederni, M.; Vincent, Q.B.; Frange, P.; Touzot, F.; Scerra, S.; Bejaoui, M.; Bousfiha, A.; Levy, Y.; Lisowska-Grospierre, B.; Canioni, D.; et al. Major histocompatibility complex class II expression deficiency caused by a RFXANK founder mutation: A survey of 35 patients. Blood 2011, 118, 5108–5118. [Google Scholar] [CrossRef] [PubMed]
- Heslop, H.E.; Brenner, M.K.; Rooney, C.M. Donor T cells to treat EBV-associated lymphoma. N. Engl. J. Med. 1994, 331, 679–680. [Google Scholar] [PubMed]
- Heslop, H.E.; Ng, C.Y.; Li, C.; Smith, C.A.; Loftin, S.K.; Krance, R.A.; Brenner, M.K.; Rooney, C.M. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med. 1996, 2, 551–555. [Google Scholar] [CrossRef] [PubMed]
- O’Reilly, R.J.; Prockop, S.; Hasan, A.; Doubrovina, E. Therapeutic advantages provided by banked virus-specific T-cells of defined HLA-restriction. Bone Marrow Transplant. 2019, 54, 759–764. [Google Scholar] [CrossRef]
- Icheva, V.; Kayser, S.; Wolff, D.; Tuve, S.; Kyzirakos, C.; Bethge, W.; Greil, J.; Albert, M.H.; Schwinger, W.; Nathrath, M.; et al. Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J. Clin. Oncol. 2013, 31, 39–48. [Google Scholar] [CrossRef]
- Bollard, C.M.; Tripic, T.; Cruz, C.R.; Dotti, G.; Gottschalk, S.; Torrano, V.; Dakhova, O.; Carrum, G.; Ramos, C.A.; Liu, H.; et al. Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed Hodgkin lymphoma. J. Clin. Oncol. 2018, 36, 1128–1139. [Google Scholar] [CrossRef]
- Koehne, G.; Doubrovin, M.; Doubrovina, E.; Zanzonico, P.; Gallardo, H.F.; Ivanova, A.; Balatoni, J.; Teruya-Feldstein, J.; Heller, G.; May, C.; et al. Serial in vivo imaging of the targeted migration of human HSV-tk-transduced antigen-specific lymphocytes. Nat. Biotechnol. 2003, 21, 405–413. [Google Scholar] [CrossRef]
- Ewer, K.J.; Lambe, T.; Rollier, C.S.; Spencer, A.J.; Hill, A.V.; Dorrell, L. Viral vectors as vaccine platforms: From immunogenicity to impact. Curr. Opin. Immunol. 2016, 41, 47–54. [Google Scholar] [CrossRef]
- Gurer, C.; Strowig, T.; Brilot, F.; Pack, M.; Trumpfheller, C.; Arrey, F.; Park, C.G.; Steinman, R.M.; Münz, C. Targeting the nuclear antigen 1 of Epstein Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses. Blood 2008, 112, 1231–1239. [Google Scholar] [CrossRef]
- Rühl, J.; Citterio, C.; Engelmann, C.; Haigh, T.A.; Dzionek, A.; Dreyer, J.H.; Khanna, R.; Taylor, G.S.; Wilson, J.B.; Leung, C.S.; et al. Heterologous prime-boost vaccination protects from EBV antigen expressing lymphomas. J. Clin. Investig. 2019, 129, 2071–2087. [Google Scholar] [CrossRef]
- Leung, C.S.; Maurer, M.A.; Meixlsperger, S.; Lippmann, A.; Cheong, C.; Zuo, J.; Haigh, T.A.; Taylor, G.S.; Münz, C. Robust T-cell stimulation by Epstein-Barr virus-transformed B cells after antigen targeting to DEC-205. Blood 2013, 121, 1584–1594. [Google Scholar] [CrossRef] [PubMed]
- Iwakiri, D.; Zhou, L.; Samanta, M.; Matsumoto, M.; Ebihara, T.; Seya, T.; Imai, S.; Fujieda, M.; Kawa, K.; Takada, K. Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from toll-like receptor 3. J. Exp. Med. 2009, 206, 2091–2099. [Google Scholar] [CrossRef] [PubMed]
- Gregorovic, G.; Boulden, E.A.; Bosshard, R.; Karstegl, C.E.; Skalsky, R.; Cullen, B.R.; Gujer, C.; Ramer, P.; Münz, C.; Farrell, P.J. Epstein-Barr viruses deficient in EBER RNAs give higher LMP2 RNA expression in lymphoblastoid cell lines and efficiently establish persistent infection in humanized mice. J. Virol. 2015, 11711–11714. [Google Scholar] [CrossRef] [PubMed]
- van Zyl, D.G.; Tsai, M.H.; Shumilov, A.; Schneidt, V.; Poirey, R.; Schlehe, B.; Fluhr, H.; Mautner, J.; Delecluse, H.J. Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice. PLoS Pathog. 2018, 14, e1007464. [Google Scholar] [CrossRef]
- Fiola, S.; Gosselin, D.; Takada, K.; Gosselin, J. TLR9 contributes to the recognition of EBV by primary monocytes and plasmacytoid dendritic cells. J. Immunol. 2010, 185, 3620–3631. [Google Scholar] [CrossRef]
- Severa, M.; Giacomini, E.; Gafa, V.; Anastasiadou, E.; Rizzo, F.; Corazzari, M.; Romagnoli, A.; Trivedi, P.; Fimia, G.M.; Coccia, E.M. EBV stimulates TLR- and autophagy-dependent pathways and impairs maturation in plasmacytoid dendritic cells: Implications for viral immune escape. Eur. J. Immunol. 2013, 43, 147–158. [Google Scholar] [CrossRef]
- Panikkar, A.; Smith, C.; Hislop, A.; Tellam, N.; Dasari, V.; Hogquist, K.A.; Wykes, M.; Moss, D.J.; Rickinson, A.; Balfour, H.H., Jr.; et al. Cytokine-mediated loss of blood dendritic cells during Epstein-Barr virus-associated acute infectious mononucleosis: Implication for immune dysregulation. J. Infect. Dis. 2015, 212, 1957–1961. [Google Scholar] [CrossRef]
- Gagnaire, A.; Nadel, B.; Raoult, D.; Neefjes, J.; Gorvel, J.P. Collateral damage: Insights into bacterial mechanisms that predispose host cells to cancer. Nat. Rev. Microbiol. 2017, 15, 109–128. [Google Scholar] [CrossRef]
- Schiller, J.T.; Lowy, D.R. Vaccines to prevent infections by oncoviruses. Annu. Rev. Microbiol. 2010, 64, 23–41. [Google Scholar] [CrossRef]
- Bartenschlager, R.; Lohmann, V.; Penin, F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat. Rev. Microbiol. 2013, 11, 482–496. [Google Scholar] [CrossRef]
- Douam, F.; Ziegler, C.G.K.; Hrebikova, G.; Fant, B.; Leach, R.; Parsons, L.; Wang, W.; Gaska, J.M.; Winer, B.Y.; Heller, B.; et al. Selective expansion of myeloid and NK cells in humanized mice yields human-like vaccine responses. Nat. Commun. 2018, 9, 5031. [Google Scholar] [CrossRef] [PubMed]
Vaccine | Elicited Immune Response | Effect on EBV Challenge | References |
---|---|---|---|
αDEC-205-EBNA1 | Low level EBNA1 specific CD4+ T cell responses | No protection | [67,79] |
EBV VLP | Late lytic antigen specific CD4+ T cell responses | No protection | [84] |
EBV VLP with EBNA1 in tegument | Late lytic antigen and EBNA1 specific CD4+ T cell responses | Protection | [84] |
© 2019 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Münz, C. Immune Control and Vaccination against the Epstein–Barr Virus in Humanized Mice. Vaccines 2019, 7, 217. https://doi.org/10.3390/vaccines7040217
Münz C. Immune Control and Vaccination against the Epstein–Barr Virus in Humanized Mice. Vaccines. 2019; 7(4):217. https://doi.org/10.3390/vaccines7040217
Chicago/Turabian StyleMünz, Christian. 2019. "Immune Control and Vaccination against the Epstein–Barr Virus in Humanized Mice" Vaccines 7, no. 4: 217. https://doi.org/10.3390/vaccines7040217
APA StyleMünz, C. (2019). Immune Control and Vaccination against the Epstein–Barr Virus in Humanized Mice. Vaccines, 7(4), 217. https://doi.org/10.3390/vaccines7040217